Search results
Results from the WOW.Com Content Network
dendreon .com. Dendreon is a biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer. It consists of a mixture of the patient's own blood cells ( autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP - GM-CSF fusion ...
Dendreon (NAS: DNDN) has thrown in the towel. Given up. Waved the white flag. Admitted defeat. And investors aren't too happy about it. The company is closing the New Jersey plant that ...
What: Shares of cancer-drug developer Dendreon (NAS: DNDN) were getting slammed today, losing 23% as investors reacted to the company's continued struggles to grow sales of its key prostate-cancer ...
This Week's Must-Watch Stock: Dendreon. ... In this week's edition, the team talks about The Atlantic's fifth annual Health Care Forum, biotechs in the news, two stocks investors need to watch ...
No stock sums up biotech investing quite like Dendreon (NAS: DNDN) , the company behind a novel prostate cancer treatment called Provenge. In what amounts to a case study on unchecked optimism ...
2011 will be remembered as the year Dendreon (NAS: DNDN) shareholders crawled under the covers and assumed the fetal position. ... often willing to take a buy or sell stance on a stock. As for ...
Dendreon Corp. (NASDAQ: DNDN) is seeing shares surge higher on Friday on an analyst upgrade. The move higher is part because Dendreon has a long history of boom and bust with large share price ...
Nuvelo was initially founded as Hyseq in August 1992 and based on DNA array technology. Hyseq's genomic platform was used to develop gene based therapeutics and diagnostics. At the rate of more than 1,000,000 human DNA samples analyzed per month during 1997, Hyseq was a large partial human gene sequence database with over 5,000,000 sequences.